Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02768805 · ClinicalTrials.gov registry record · Phase 2
Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults
A Phase 2 study, sponsored by Medicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 900
- Enrollment target
NCT02768805: Completed Phase 2 study, sponsored by Medicago.
NCT02768805 is a Phase 2 study that has completed, run by Medicago. The registered enrollment target is 900 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (577% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02768805, a Phase 2 study, has completed, sponsored by Medicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 900 participants
- Enrollment target
Study Summary
This Phase 2 Quadrivalent VLP Vaccine study is intended to replicate and extend the immunogenicity and safety results obtained in earlier Phase 1-2 and Phase 2 studies. The study is being conducted to demonstrate that the immunogenicity profile of the Quadrivalent VLP Vaccine meets the US Center for Biologics Evaluation and Research (CBER) licensure criteria. The study will also help to define the optimal dose, establish potential competitive advantages, and support the design of future studies.
Primary Outcome
Immunogenicity will be assessed by the geometric mean titers (GMT) of hemagglutination inhibition (HI) antibody against the homologous influenza strains
Interventions
- BIOLOGICAL 15 µg/strain of Quadrivalent VLP Vaccine
- BIOLOGICAL 30 µg/strain of Quadrivalent VLP Vaccine
- BIOLOGICAL 15 µg/strain of the licensed quadrivalent vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2016-03-02 |
| Est. Completion | 2016-11-26 |
| Phase | Phase 2 |
What the finished NCT02768805 record still lists
NCT02768805 is an interventional study that assigns participants to a tested intervention. The registered 900 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (577% higher).
The record links to 0 conditions, and to 3 interventions - of which 15 µg/strain of Quadrivalent VLP Vaccine is the first listed.
NCT02768805 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02768805 about?
NCT02768805 is a clinical study titled "Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults". This Phase 2 Quadrivalent VLP Vaccine study is intended to replicate and extend the immunogenicity and safety results obtained in earlier Phase 1-2 and Phase 2 studies. The study is being conducted to demonstrate that the immunogenicity profile of the Quadrivalent VLP Vaccine meets the US Center for...
What is the current status of trial NCT02768805?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 900 participants. The study started on 2016-03-02. Estimated completion is 2016-11-26.
What interventions are being tested in trial NCT02768805?
The interventions under investigation include: 15 µg/strain of Quadrivalent VLP Vaccine (BIOLOGICAL), 30 µg/strain of Quadrivalent VLP Vaccine (BIOLOGICAL), 15 µg/strain of the licensed quadrivalent vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02768805?
This trial is sponsored by Medicago, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02768805's enrollment target sits among peer trials
900 30th of 2000 higher than 1,968 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
- NCT02960022 · 900 participants · Phase 2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI